Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 13Gynecologic 4Genitourinary 4Thoracic 3Other hematologic neoplasm 3Head & Neck 3Tumor-Agnostic 2Other solid neoplasm 2Other 2Endocrine 2CNS 2Sarcoma 1Lymphoid 1Classical hematology 1Breast 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Solutions × Tumor-Agnostic × Clear all
NCT04675021 2021-01-26

Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects

AstraZeneca

Phase 1 Completed
8 enrolled
Tumor-Agnostic

Neoplasms

NCT03348826 2020-09-16

Study of Sodium Bicarbonate in Restoring Blocked Catheters

University Health Network, Toronto

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡